Washington, October 20, 2025-Obesity has become a "silent killer" in the United States' public health landscape. According to the latest data from the Centers for Disease Control and Prevention (CDC), the adult obesity rate in the United States reached 40.3% in 2024, with severe obesity accounting for 9.4%, affecting over 100 million people. Faced with this grim reality, a class of peptide drugs called GLP-1 receptor agonists is rapidly emerging as a game-changer in weight management. These synthetic peptides, based on gut hormones, not only effectively suppress appetite and promote satiety, but also have the potential to reshape the health landscape of Americans.
GLP-1 (glucagon-like peptide-1) agonists, such as semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro), were originally used to treat type 2 diabetes, but their potential for weight loss has been widely recognized in recent years. Clinical trials have shown that patients using these drugs can achieve an average weight loss of 15%-20%, far exceeding traditional diet and exercise interventions. This trend accelerated further in 2025: a study from the Johns Hopkins School of Public Health found that one in seven bariatric surgery patients switched to GLP-1 drugs as their first option. "These peptides are more than just weight loss tools; they've shown remarkable success in improving blood sugar control and reducing cardiovascular risk," said Mary Ann Pappas, professor of nutrition at Johns Hopkins and the study's lead author. "This represents a turning point for states with high obesity rates like Mississippi, where adult obesity rates exceed 40%."
Recent progress is encouraging. At the end of September, Nature reported that a new oral GLP-1 drug, orforglipron, significantly outperformed the placebo group in a 72-week clinical trial, achieving an average weight loss of 7.5% in participants. Unlike traditional injectables, this innovative daily-pill peptide significantly improves patient compliance. Pharmaceutical giant Eli Lilly expects the drug to receive FDA approval in 2026. Furthermore, Israeli biotech company PolyPid recently unveiled a long-acting GLP-1 delivery platform that can extend drug release to several months, promising significant market potential for treating diabetes and obesity.
Experts also emphasize the "high-quality weight loss" benefits of these peptide-based drugs. In June, the American Diabetes Association released research showing that new-generation GLP-1 therapies can better preserve muscle mass, avoiding the "weight loss trap" common in traditional weight loss-fat loss and muscle loss. "This isn't just about losing weight, it's about improving overall health," said Dr. Sarah Johnson, a clinical psychologist with the American Psychological Association (APA). "GLP-1s can also reduce 'food noise'-the persistent craving for high-calorie foods-and thus improve mental health."
However, peptide-based weight loss isn't without its challenges. In September, the FDA issued a warning regarding the illegal sale of unapproved GLP-1 generics, such as semaglutide and retatrutide. These products can cause serious side effects, including the risk of pancreatitis and thyroid cancer. Furthermore, high prices (hundreds of dollars per month) and supply shortages remain obstacles. Despite this, a 2025 GLP-1 pipeline update indicated that at least five new drugs had entered Phase III trials, with approval expected by 2028.
With obesity rates in rural areas of the United States continuing to rise compared to urban areas (by 3 percentage points in 2024), peptide drugs are seen as central to the "next wave of weight loss." Professor David Ludwig, a researcher at the Harvard School of Public Health, optimistically predicted, "If policies support expanded insurance coverage, these drugs could reduce the national obesity rate by 5%-10%." Amid this overweight crisis, peptide innovation may be a ray of hope-but only if it is combined with safe use and a sustainable lifestyle.
